Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
Catalent, Inc. (NYSE: CTLT) (“Catalent”), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the third quarter of fiscal 2024, which ended March 31, 2024.
- Catalent, Inc. (NYSE: CTLT) (“Catalent”), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the third quarter of fiscal 2024, which ended March 31, 2024.
- “I am pleased to report that in the fiscal third quarter Catalent returned to growth, including double-digit non-COVID year-on-year revenue growth.
- Additionally, we achieved record third quarter non-COVID customer wins, and our non-COVID customer wins in the first three quarters of the fiscal year increased double digits over the prior year.
- Third quarter fiscal 2024 Adjusted EBITDA(1) was $163 million, or 15.1% of net revenue, compared to $105 million, or 10.1% of net revenue, in the third quarter a year ago.